Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options

Area of Science:

• Pulmonary Medicine
• Respiratory Pharmacology

Background:

• Chronic obstructive pulmonary disease (COPD) is a leading global cause of illness and death.
• COPD involves pulmonary inflammation, airway remodeling, and impaired mucociliary function, leading to airflow limitation.
• Mucociliary dysfunction in COPD stems from mucus hypersecretion and reduced mucus transport, necessitating targeted treatments.

Purpose of the Study:

• To review the role of mucociliary dysfunction in COPD.
• To evaluate current and potential therapeutic strategies for improving mucociliary function in COPD.
• To explore the impact of bronchodilators, particularly long-acting beta2-agonists (LABAs), on COPD mucociliary clearance.

Main Methods:

• Literature review of current COPD guidelines and pharmacological treatments.
• Analysis of the pathophysiological mechanisms of mucociliary dysfunction in COPD.
• Examination of the effects of different bronchodilator classes on mucociliary function.

Main Results:

• Current guidelines do not recommend mucolytics for stable COPD.
• Long-acting beta2-agonists (LABAs) show potential for improving COPD mucociliary function beyond bronchodilation.
• Combination therapy with LABAs and inhaled corticosteroids may offer broader benefits by addressing inflammation and indirectly improving clearance.

Conclusions:

• Mucociliary dysfunction is a key feature of COPD requiring specific treatment considerations.
• LABAs represent a promising therapeutic option for enhancing mucociliary clearance in COPD.
• Further research into novel targets for airway mucociliary dysfunction is ongoing.